Abstract Autosomal recessive polycystic kidney disease (ARPKD) is characterized by enlarged kidneys with dilated collecting ducts and congenital hepatic fibrosis. There is a variable rate of progression of kidney and liver disease. Portal hypertension and Caroli's disease occur from liver involvement that contributes to morbidity and mortality. Approximately 40 % of patients have a severe disease phenotype leading to rapid onset of end-stage kidney disease (ESKD) and signs of portal hypertension and the rest may have predominant involvement of either the kidney or liver. It is important for the physician to establish the extent of organ involvement before deciding on the ultimate plan of management, especially when transplantation is required. Isolated renal transplantation can be considered when liver involvement is minimal. If hepatobiliary disease is prominent, and kidney function is preserved, management options are based on individual characteristics. In the presence of significant liver disease and ESKD, consideration should be given to combined liver kidney transplantation, which can be beneficial in eliminating the consequences of both kidney and liver disease. However, this is a complex surgical procedure that needs to be performed at experienced transplant centers. Improvement in surgical techniques has considerably improved short-term graft survival with the added advantage of the liver offering immunologic protection to the kidney allograft.
Introduction
Autosomal recessive polycystic kidney disease (ARPKD) is a fibrocystic disease that affects both the kidney and liver. It is caused by mutations in the PKHD1 gene that is located on chromosome 6 and encodes a protein fibrocystin/polyductin found in primary cilia of renal tubular and biliary epithelial cells [1] [2] [3] [4] [5] . The disease is heterogeneous and characterized by fusiform dilatation of renal collecting ducts and dysgenesis of hepatic biliary ducts. Fifty percent of the patients affected manifest in the neonatal period [2] . The rest are recognized later and can present at any time from infancy to adulthood.
Polycystic kidney disease and congenital hepatic fibrosis are the most common clinical manifestations of the disease [4] [5] [6] . Pancreatic cysts and cerebral aneurysms have been rarely described in single case reports [7] [8] [9] [10] . Individuals with two truncating mutations have a severe clinical phenotype, whereas those with amino acid substitutions have a less lethal presentation [4] . However, there is wide variability in the onset of clinical manifestations and rate of progression of kidney disease even in patients carrying the same PKHD1 mutation, suggesting modifying genes and environmental factors play an important role in phenotypic presentation [4] .
Clinical presentation
Antenatal and neonatal presentation is characterized by the presence of markedly enlarged kidneys, resulting in respiratory compromise and limitations in enteral feeding. Thirty percent of affected neonates die from respiratory failure and pulmonary hypoplasia [2] . Neonates with large echogenic kidneys have ectasia of 60-90 % of the renal collecting tubules and generally have hypertension and decreased kidney function [1, 2] . Beyond the neonatal period, hypertension occurs early in two-thirds of children [1] . There is a variable rate of progression of kidney and liver disease. Children may have advanced failure of more than one organ or predominant failure of one organ with a wide range of clinical severity. Kidneys with ARPKD do not increase in size after the first 2-3 years of life [1, 2] . Those with corticomedullary involvement versus only medullary involvement have worse kidney function [11] . Survival into mid-adulthood without requiring liver or renal replacement therapy has been described [12, 13] . There is also considerable intra-familial variability [4] .
Fetal morphologic studies have revealed malformation of the biliary ductal plate and associated abnormalities of the portal veins in ARPKD [14, 15] . Ductal plate malformations occur as a consequence of derangement in remodeling of the developing fetal biliary ductal system. A spectrum of pathologic biliary abnormalities can occur ranging from extrahepatic choledochal cysts to intrahepatic ductal dilatation and cyst formation. Ductal plate malformations result in persistence of primitive bile ducts, aberrant interlobular bile duct proliferation, and expansion of portal areas with an excess of embryonic bile ducts and fibrous tissue. Caroli's disease is characterized by non-obstructive, segmental, communicating saccular or fusiform dilatation of the large intra-hepatic bile ducts [16] . The defect may be localized or diffuse. When both Caroli's disease and congenital hepatic fibrosis occur, it is termed Caroli's syndrome. Hepatocellular dysfunction is rare, and when present, is not typically seen until late. However, portal hypertension and abnormalities of the biliary tract are common and manifest long before loss of synthetic function of the liver. Overt clinical manifestations of hepatobiliary disease have been noted in 46-83 % of children [2] [3] [4] . The signs are hepatic enlargement or heterogeneous and echogenic appearance of the liver by ultrasound, splenomegaly, hypersplenism, esophageal varices, protein-losing enteropathy, and ascending cholangitis [2, 3] . Enlargement of the left lobe of the liver is a consistent finding [11] . Patients with Caroli's disease are at risk for acute bacterial cholangitis leading to septicemia and biliary tract calculi from stasis. Gram-negative organisms and occasionally Gram-positive anaerobes and fungi are implicated in acute cholangitis requiring broad-spectrum antibiotic coverage [17] . Fever, right upper quadrant pain, icterus, and abnormal transaminases could indicate cholangitis but often the presentation can be subtle. A significant number of children have succumbed to the complications of biliary disease after transplantation [18] [19] [20] [21] . Extrahepatic biliary disease as the predominant manifestation has also been reported [9] . Ascites, hepatopulmonary syndrome, portopulmonary disease, and hepatic encephalopathy are less common. The development of ascites should herald further evaluation for other underlying issues such as portal vein thrombosis or loss of peritoneal exchange space caused by recurrent peritonitis [3] . Hepato-pulmonary syndrome is a complication of portal hypertension and is characterized by impaired oxygenation in the upright position, intra-pulmonary vascular dilatations, and the presence of portal hypertension. This has been described with congenital hepatic fibrosis [22, 23] .
The following case scenarios reflect the heterogeneity of clinical presentation.
Case 1 A 5-year-old Hispanic male was diagnosed with ARPKD soon after birth when he was noted to have mild renal insufficiency and hypertension. He had a progressive and rapid increase in kidney size resulting in feeding difficulties and decreased respiratory reserve. In order to facilitate and optimize feedings, a left nephrectomy was performed at 7 months of age, after which his serum creatinine increased from 0.8 to 1.2 mg/dl. Thereafter, he had progressive deterioration of renal function and worsening hypertension. He had a right nephrectomy at 16 months of age and was placed on peritoneal dialysis for 1 year. Following an episode of fungal peritonitis, he was switched to hemodialysis. He was n o t e d t o h a v e h e p a t o s p l e n o m e g a l y a n d hypersplenism at the age of two and had intermittent elevations of liver enzymes during periods of acute illness. Liver biopsy was consistent with congenital hepatic fibrosis and early cirrhosis. He had no episodes of gastro-intestinal bleeding. Magnetic resonance cholangiopancreatography (MRCP) revealed mild dilatation of the intra-hepatic biliary ducts and high T2 signal intensity throughout the periphery of the liver. Therefore, with clinical evidence of portal hypertension, the consensus was to list him for a combined liver kidney transplant. At an age of 3.5 years, (weight 13.5 kg), he had a combined "en bloc" liver kidney transplant. Pathologically, the liver was described as being cirrhotic with intraductal cholestasis (Fig. 1a and b In the first case, a decision was made for a combined liver kidney transplant based on his ESKD and clinical evidence of portal hypertension. There were several inter-disciplinary team discussions regarding surgical options in this child. If he had an isolated kidney transplant, a porto-systemic shunt could be performed when he developed worsening signs of portal hypertension. However, this could expose this small child to further complications such as shunt thrombosis and could complicate future liver transplantation. A combined liver kidney transplant (CLKT) in this child would give him the benefit of having two organs from the same donor and prevent the consequences of worsening portal hypertension. Moreover, transient elevation of liver enzymes during his febrile illnesses could have been attributed to cholangitis that may have been masked by peritonitis. Therefore, the ultimate decision was to give him a CLKT. This patient has been followed for 2 years since the transplant. The second case had advanced chronic kidney disease with no evidence of Caroli's disease or portal hypertension, but had an abnormality of the common bile duct. This patient has been followed by us for the last 12 years. An MRCP is planned for future follow-up. This patient had no previous history suggestive of surgery or inflammatory disease of the hepatobiliary system that could explain the stricture. The third case had portal hypertension with preserved renal function. An isolated liver transplant could also have been considered in this patient. However, this was deferred so that the option of CLKT could be considered if needed in the future. He has been followed for the last 7 years and continues to maintain stable liver and kidney function. These cases demonstrate the wide variability in phenotypic expression of ARPKD thus illustrating the need to individualize management. The underlying pathophysiologic mechanisms resulting in phenotypical variability are yet to be elucidated. Kidneys with ARPKD are very large, have poor corticomedullary differentiation, and grow rapidly in early infancy. As the child grows, the rate of growth of the kidneys slows down. High-resolution ultrasonography helps in determining the extent of renal involvement in patients with milder forms of renal disease where ductal dilatation may be present predominantly in the medullary region [11] . The prevalence of hepatic abnormalities is underestimated in children. Every effort should be made to systematically screen children with the diagnosis of ARPKD for hepato-biliary disease. Investigations in a child with ESKD and ARPKD should be geared towards diagnosing portal hypertension and Caroli's disease (See Fig. 2 ). Conventional and Doppler ultrasonography to determine the size of the spleen, direction of flow in the portal venous system, liver size and echogenicity, complete blood and platelet count to assess hypersplenism, and upper endoscopy to look for esophageal varices help assess the presence of portal hypertension. Magnetic resonance cholangiopancreatography or triple-phase CT scan are useful tools to assess saccular and cystic dilatation of the intrahepatic ducts, venous collaterals around the portal vein, and a patent umbilical vein. Liver biopsy should be considered and may be helpful in making the diagnosis and to define the magnitude of the liver disease when it is in doubt. However, in the presence of advanced liver disease and multiple liver cysts, liver biopsy is associated with an increased risk of bleeding and infection. A transjugular biopsy may be considered if there is a strong indication. Histological confirmation alone will not help in determining management. Most often, sufficient diagnostic information is obtained based on clinical, laboratory features, and imaging studies.
Hepatopulmonary syndrome (HPS) is a complication associated with portal hypertension and is clinically manifested by hypoxemia in the upright posture and objective signs of arterial blood oxygenation differences due to intrapulmonary shunts (see Fig. 2 ). Although HPS is recognized with greater frequency in cirrhotic children, it has also been described in non-cirrhotic portal hypertension [23, 24] . When HPS is suspected, technetium-labeled albumin perfusion scintigraphy and contrast-enhanced echocardiography are useful diagnostic tests to evaluate pulmonary vascular dilatation and intrapulmonary arteriovenous shunts [24] .
Genetic diagnosis may be important early in pregnancy when there is an affected sibling or if the diagnosis is in question [2] . The PKHd1 gene is a very large gene with a complicated splicing pattern and makes genetic testing time consuming, expensive, and labor intensive. There is marked allelic heterogeneity and most patients are compound heterozygotes [25] . 
Renal transplantation

Treatment and prevention of variceal bleeding
Recent expert opinion suggests endoscopic band ligation is favorable over sclerotherapy in eradication of varices [27] . After a first variceal bleed, serial sessions are performed every 2-4 weeks until eradication of varices or a total of five sessions. Re-bleeding, recurrence of varices, and development of gastric varices can occur. Sclerotherapy can be considered in children too small to undergo ligation but is inferior to ligation given increased risks of procedure. There are no current guidelines for primary prophylaxis of the first gastrointestinal bleeding episode. However, endoscopic ligation can be considered when there is an increased risk of morbidity and mortality from the first variceal bleed [27, 28] . There is no data available on safety and dosing of nonselective betablockers, which are not currently recommended for routine use in children [27] .
Portosystemic shunting
Endoscopic therapies do not alter pressure in the portal system and redistribution of blood can occur at other sites in the portal system [29] . Hence, in patients who fail endoscopic treatment for prevention of re-bleeding, surgical portosystemic shunting is recommended, especially if prognosis is expected to be good within the next 5 years. Transjugular intrahepatic portosystemic shunting (TIPS) can be considered if the patient is considered at a high risk for surgical shunting or as bridge to transplantation in cases of persistent bleeding and poor 5-year expected outcome [29, 30] . Very few porto-systemic shunts Anecdotal reports of management of portal hypertension in children with portosystemic shunts have been reported in ARPKD [33] . However, the kidney is a major source of ammonia disposal in the presence of decreased hepatic ammonia detoxification [34] [35] [36] . This compensatory mechanism is limited with significant renal dysfunction. Placement of a shunt in a child with ESKD can increase the risk of hepatic encephalopathy from hyperammonemia [37] . Portosystemic shunt may be considered after successful renal transplantation.
Isolated liver transplantation
There is increased morbidity and mortality from sepsis associated with cholangitis [38] . If there is no evidence of advanced chronic kidney disease, liver transplantation alone can be considered in the setting of recurrent episodes of cholangitis, which can occur with intrahepatic duct dilatation or associated with Caroli's disease or syndrome [39] . Recurrent episodes of cholangitis can hasten liver damage and biliary cirrhosis. Although cholangiocarcinoma has not been reported in children with ARPKD, adults are at higher risk for this complication. Liver transplantation is indicated in decompensated cirrhosis, refractory portal hypertension, and hepatopulmonary syndrome [39] . Partial hepatectomy can be considered in patients with monolobar Caroli's disease, thus sparing the patient from immunosuppression that is required with orthotopic liver transplantation [40] . have severe renal and hepatobiliary phenotype and could be potential candidates for CLKT [6] . Mortality in 60-80 % of patients with kidney transplants from ARPKD is from hepatobiliary disease [21] . Surgical mortality from liver transplantation in recent years has decreased to <10 % at 1 year. It has been suggested that in a select group of patients, combined liver kidney transplantation is a viable option [48] . Children with ARPKD will not have a high Pediatric End Stage Liver Disease (PELD) score as they have normal hepatocellular function for a long time despite developing portal hypertension and cholangitis. Therefore the PELD score does not adequately reflect the morbidity and mortality associated with cholangitis. An exception has to be requested if a decision is made that CLKT will be beneficial in a given situation.
Combined liver kidney transplantation
Technical aspects of CLKT
Adequate preservation with cold electrolyte solutions and short cold ischemia times are vital for CLKT. Simultaneous or sequential liver kidney transplantation are some of the options. In simultaneous CLKT, the organs are obtained from the same donor. Matching the size of the donor to the recipient is important for post-operative recovery [47] . Whole liver grafts, split grafts, en bloc or reduced grafts are used depending on the size of the recipient. The liver graft is implanted first to shorten the cold ischemia time followed by the kidney, which is implanted extraperitoneally, from a separate incision in the right or left lower quadrant. Alternatively, the kidney can be implanted intra-abdominally. One of the approaches at our institution is to implant the kidney graft 18-24 h after the liver graft while maintaining the kidney on machine perfusion, which has been demonstrated to reduce preservation injury during reperfusion [49, 50] . This shortens the surgical time for each organ transplant and allows recovery of the liver transplant. The patient is maintained on CRRT during the interval between liver and kidney transplantation.
Conventional liver transplantation involves clamping of the recipient IVC and portal vein with subsequent removal of the recipient's liver and retro-hepatic vena cava [51] . This is then replaced with the donor segment of vena cava and liver. An alternative approach that has been used is the piggyback technique, wherein the recipient's inferior vena cava (IVC) is preserved and partial clamping of the IVC is possible, thus mitigating the complication of decreased venous return to the heart and venous congestion in the intestinal capillary bed [52] [53] [54] [55] . The piggyback technique is associated with a reduction in surgical time and warm ischemia time, decreased need for blood products, and reduction in 30-day mortality [55] . In small pediatric recipients, the organs can be placed "en bloc" where the liver and kidney are harvested with the donor aorta and IVC, which are anastomosed to the recipient aorta and IVC. This is followed by the donor and recipient portal vein and biliary tract anastomosis. This technique is advantageous in small recipients with size-matched donors [56, 57] . CLKT can be technically demanding and time consuming. Varying degrees of hemodynamic instability can be observed throughout the surgery, and the anhepatic phase is most turbulent. Patients with liver disease often develop lactic acidosis, especially in the anhepatic phase. This is worsened by renal failure and is difficult to correct by conventional methods. Hyperkalemia occurs after unclamping of the portal vein during reperfusion of the donor liver resulting in arrhythmias and hemodynamic instability. Pre-existing renal impairment, increased baseline serum potassium, multiple transfusions of blood, and ischemia reperfusion injury contribute to hyperkalemia [61] . Pre-reperfusion flushing of the graft with lactated Ringer's solution is a helpful strategy to ameliorate this.
Peri-operative management of CLKT
Intra-operative CRRT Intra-operative renal replacement therapy helps to manage metabolic acidosis and maintain potassium at lower levels. Depending on the hemodynamic status of the recipient, fluid balance can be adjusted. Acute increases in potassium may still need to be managed with drugs that drive potassium intra-cellularly [62] . Since most patients with ARPKD do not have end-stage liver disease, a low dose of anti-coagulation is used to maintain filter patency and this should be communicated with the surgeon. CRRT is started after induction of anesthesia before commencement of surgery. Adjustments are made to the prescription periodically depending on the electrolytes, CVP, and blood pressure. Monitoring hemodynamic status can be a challenge, as CVP may not be reliable because increased intra-abdominal pressures, and positive end expiratory pressure, can affect CVP. Although there are limited indications for the use of pulmonary catheters in children, they can be considered during CLKT, as useful intra-operative data can be obtained from direct measurements of right heart pressures and cardiac output. However, its use is currently limited to pediatric patients with pulmonary hypertension and refractory shock. Transesophageal echocardiography can be an additional tool to determine the dynamic function of the heart and contractility.
Post-operative course In the immediate post-operative period, most patients are in significant positive fluid balance. These patients may need a longer duration of mechanical ventilation compared to isolated organ transplantation [47] . In some instances, the abdominal wall is closed temporarily in small-sized recipients until edema improves. After 2-3 days, the abdominal wall is closed. The patency of the vasculature is assessed on a daily basis by Doppler ultrasound to monitor the possibility of post-operative thrombosis.
Clinical and therapeutic dilemmas
Overt clinical manifestations of hepatobiliary disease are not evident in all patients with ARPKD who have clinical signs of renal disease and the converse is also true. Therefore it is important to perform a thorough investigation if transplantation or an invasive procedure is being considered, so that appropriate decisions are made. Clinical decision-making is further complicated by the fact that the rate of progression of disease in each organ is variable. It is very difficult to predict the rate of progression of portal hypertension or intrahepatic ductal dilatation. In the case series described from Beunoyer et al., a significant proportion of patients had portal hypertension and cholangitis at baseline [18] . Their group opted to perform isolated kidney transplantation in all of them. Posttransplant, two of ten (20 %) required surgical intervention for hepatobiliary disease. Khan et al. reported significant morbidity and mortality from cholangitis in their series of children with intrahepatic duct dilatation who had an isolated renal transplant [20] . Each center's approach to transplantation in the very young patient varies. Animal models suggest that intraductal dilatation is a progressive phenomenon and it is unclear if this is also true for human ARPKD. Thus, patients with an isolated renal transplantation have to be closely monitored for worsening of portal hypertension and progression of intrahepatic ductal dilatation.
One approach to a patient with neonatal or infantile ARPKD and ESKD is to provide a kidney transplant and address the complications of portal hypertension as they arise. One will need periodic screening for esophageal varices, which can be managed with endoscopic band ligation or a portosystemic shunt if indicated. Pancytopenia can be a problem, and may prompt changes in immune suppression leading to increased risk of rejection. Ascites can develop with worsening portal hypertension. At that point, liver transplant can be considered. Recurrent episodes of cholangitis can be associated with considerable morbidity and mortality, especially after isolated kidney transplantation. The typical saccular dilatations of the intra-hepatic biliary system may not develop in very young children. However, they may still be susceptible to cholangitis without overt evidence of Caroli's disease. A crucial question that will need to be answered is if CLKT offers a survival benefit for the patient and graft in children with ARPKD compared to isolated kidney transplantation. Studies in adult populations cannot be extrapolated to the pediatric population as CLKT is done for other indications. Kidney graft survival and rejection-free survival has been shown to be better in CLKT compared to kidney transplantation after liver transplantation [63] .
Conclusions
In a child with ESKD who has no evidence of portal hypertension, Caroli's disease or episodes of recurrent cholangitis, isolated kidney transplantation is a good option. Periodic follow-up for monitoring the development of liver disease is suggested. When portal hypertension is associated with variceal bleeding, but liver and kidney function are preserved, endoscopic band ligation can be considered. If there is a repetitive need for endoscopic band ligation, porto-systemic shunting is an option. Liver transplant is considered in the setting of severe portal hypertension refractory to medical management, Caroli's disease, recurrent cholangitis, or loss of synthetic liver function. In a child with ESKD and overt evidence of portal hypertension and/or Caroli's disease and recurrent cholangitis, combined liver kidney transplantation can be beneficial in eliminating the consequences of both kidney and liver disease in ARPKD. Furthermore, there is evidence that the liver offers immunologic protection over the kidney [64, 65] . Transplanting two organs from the same donor has been associated with a decreased risk of rejection. The added advantage of a liver transplant is that a single agent can be eventually used for immunosuppression. The benefit of CLKT will have to be balanced with the morbidity, mortality, and complexity associated with this major surgical procedure and the experience of the transplant center. 
